Technical Analysis for AFMD - Affimed Therapeutics B.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.72 | -0.09% | 0.00 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -0.09% | |
| Volume Surge | Other | -0.09% | |
| Lower Bollinger Band Walk | Weakness | -0.09% | |
| New 52 Week Low | Weakness | -0.09% | |
| Wide Bands | Range Expansion | -0.09% | |
| Below Lower BB | Weakness | -0.09% | |
| Down 3 Days in a Row | Weakness | -0.09% | |
| Down 4 Days in a Row | Weakness | -0.09% | |
| Down 5 Days in a Row | Weakness | -0.09% | |
| Lower Bollinger Band Touch | Weakness | -0.09% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| New 52 Week Low | about 3 hours ago |
| Reversed from Up | about 3 hours ago |
| 3x Volume Pace | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 11/14/2024
Affimed Therapeutics B.V. Description
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Clinical Development Monoclonal Antibodies Lymphoma Immunotherapies Prostate Cancer Blastoma Glioblastoma Epidermal Growth Factor Receptor Hematologic Malignancies Natural Killer Cell Chronic Lymphocytic Leukemia Lymphocytic Leukemia Head And Neck Cancer Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Entospletinib Hodgkin Lymphoma Non Hodgkin Lymphoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.95 |
| 52 Week Low | 2.72 |
| Average Volume | 103,657 |
| 200-Day Moving Average | 4.79 |
| 50-Day Moving Average | 3.43 |
| 20-Day Moving Average | 3.44 |
| 10-Day Moving Average | 3.50 |
| Average True Range | 0.25 |
| RSI (14) | 28.06 |
| ADX | 24.76 |
| +DI | 16.07 |
| -DI | 30.30 |
| Chandelier Exit (Long, 3 ATRs) | 3.28 |
| Chandelier Exit (Short, 3 ATRs) | 3.48 |
| Upper Bollinger Bands | 4.02 |
| Lower Bollinger Band | 2.85 |
| Percent B (%b) | -0.11 |
| BandWidth | 34.14 |
| MACD Line | -0.07 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0841 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.19 | ||||
| Resistance 3 (R3) | 3.24 | 3.13 | 3.11 | ||
| Resistance 2 (R2) | 3.13 | 3.01 | 3.11 | 3.08 | |
| Resistance 1 (R1) | 2.93 | 2.94 | 2.88 | 2.88 | 3.06 |
| Pivot Point | 2.82 | 2.82 | 2.80 | 2.80 | 2.82 |
| Support 1 (S1) | 2.62 | 2.70 | 2.57 | 2.57 | 2.38 |
| Support 2 (S2) | 2.51 | 2.63 | 2.49 | 2.36 | |
| Support 3 (S3) | 2.31 | 2.51 | 2.33 | ||
| Support 4 (S4) | 2.26 |
